openPR Logo
Press release

Adrenoleukodystrophy Pipeline 2024 | Bluebird bio, Applied Genetic Technologies Corporation, Poxel, Minoryx Therapeutics, Orpheris, MedDay Pharmaceuticals, Viking Therapeutics, and others.

06-19-2024 05:59 AM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Adrenoleukodystrophy Pipeline

Adrenoleukodystrophy Pipeline

DelveInsight's, "Adrenoleukodystrophy Pipeline Insight 2024" report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in the Adrenoleukodystrophy pipeline landscape. It covers the Adrenoleukodystrophy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Adrenoleukodystrophy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Adrenoleukodystrophy Pipeline Report
• DelveInsight's Adrenoleukodystrophy pipeline report depicts a robust space with 8+ active players working to develop 8+ pipeline therapies for Adrenoleukodystrophy treatment.
• The leading companies working in the Adrenoleukodystrophy Market include Bluebird bio, Applied Genetic Technologies Corporation, Poxel, Minoryx Therapeutics, Orpheris, MedDay Pharmaceuticals, Viking Therapeutics, and others.
• Promising Adrenoleukodystrophy Pipeline Therapies in the various stages of development include Leriglitazone, MIN-102, VK0214, MD1003 100 mg capsule, SBT101, Cholic Acids, OP-101, and others.
• April 2024:- BlueBird Bio- A Postmarketing, Prospective, Multicenter, Observational, Long-Term Safety and Effectiveness Registry Study of Patients With Cerebral Adrenoleukodystrophy (CALD) Treated With Elivaldogene Autotemcel (Stargazer). The main aim of this study is to assess and describe the safety outcomes, including newly diagnosed malignancies, of patients with CALD treated with eli-cel in the post-marketing setting (tradename Skysona) and to describe major functional disability (MFD)-free survival over time in participants with more advanced early active CALD. All enrolled participants with CALD treated with eli-cel in the post-marketing setting will be followed in this study for 15 years.
• March 2024:- Minoryx Therapeutics, S.L.- A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy. A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adults Male Subjects with Cerebral Adrenoleukodystrophy.

Request a sample and discover the recent advances in Adrenoleukodystrophy Treatment Drugs @ Adrenoleukodystrophy Pipeline Report- https://www.delveinsight.com/report-store/adrenoleukodystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

In the Adrenoleukodystrophy pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Adrenoleukodystrophy NDA approvals (if any), and product development activities comprising the technology, Adrenoleukodystrophy (ALD) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Adrenoleukodystrophy Overview
Adrenoleukodystrophy (ALD) is a rare, X-linked metabolic disorder. ALD is caused by mutations in the ABCD1 gene that affect the production of adrenoleukodystrophy protein (ALDP) and subsequently cause toxic accumulation of very long-chain fatty acids (VLCFAs) primarily in the adrenal cortex and white matter of the brain and spinal cord.

Find out more about Adrenoleukodystrophy Therapeutics Assessment @ Adrenoleukodystrophy Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/adrenoleukodystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Adrenoleukodystrophy Emerging Drugs Profile
• Elivaldogene autotemcel: bluebird bio
• Leriglitazone: Minoryx Therapeutics

Adrenoleukodystrophy Pipeline Therapeutics Assessment
There are approx. 8+ key companies which are developing the Adrenoleukodystrophy therapies. The Adrenoleukodystrophy companies which have their Adrenoleukodystrophy (ALD) drug candidates in the most advanced stage, i.e. Phase III include, bluebird bio.

DelveInsight's Adrenoleukodystrophy pipeline report covers around 8+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Adrenoleukodystrophy Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type

Adrenoleukodystrophy Pipeline Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Learn more about the emerging Adrenoleukodystrophy Pipeline Therapies @ Adrenoleukodystrophy Clinical Trials Assessment- https://www.delveinsight.com/sample-request/adrenoleukodystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Adrenoleukodystrophy Pipeline Report
• Coverage- Global
• Adrenoleukodystrophy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Adrenoleukodystrophy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Adrenoleukodystrophy Companies- Bluebird bio, Applied Genetic Technologies Corporation, Poxel, Minoryx Therapeutics, Orpheris, MedDay Pharmaceuticals, Viking Therapeutics, and others.
• Adrenoleukodystrophy Pipeline Therapies- Leriglitazone, MIN-102, VK0214, MD1003 100 mg capsule, SBT101, Cholic Acids, OP-101, and others.

Dive deep into rich insights for new drugs for Adrenoleukodystrophy Treatment, Visit @ Adrenoleukodystrophy Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/adrenoleukodystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Adrenoleukodystrophy Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Adrenoleukodystrophy (ALD) - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Adrenoleukodystrophy (ALD) Collaboration Deals
9. Late Stage Products (Preregistration)
10. Elivaldogene autotemcel: bluebird bio
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II/III)
13. Leriglitazone: Minoryx Therapeutics
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. OP 101: Orpheris
17. Drug profiles in the detailed report…..
18. Preclinical/Discovery Stage Products
19. Research programme: Adrenoleukodystrophy gene therapy: AGTC
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Adrenoleukodystrophy Companies
23. Adrenoleukodystrophy Products
24. Adrenoleukodystrophy Unmet Needs
25. Adrenoleukodystrophy Market Drivers and Barriers
26. Adrenoleukodystrophy Future Perspectives and Conclusion
27. Adrenoleukodystrophy Analyst Views
28. Adrenoleukodystrophy Companies
29. Appendix

For further information on the Adrenoleukodystrophy Pipeline therapeutics, reach out to Adrenoleukodystrophy Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/adrenoleukodystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

List of Important Links-
Uveitis Market- https://www.delveinsight.com/report-store/uveitis-market
Hidradenitis Suppurativa Market- https://www.delveinsight.com/report-store/hidradenitis-suppurativa-market
Peripheral T-cell Lymphoma Market- https://www.delveinsight.com/report-store/peripheral-t-cell-lymphoma-ptcl-market
Glaucoma Market- https://www.delveinsight.com/report-store/glaucoma-market
Retinitis Pigmentosa Market- https://www.delveinsight.com/report-store/retinitis-pigmentosa-market
Oropharyngeal Cancer Market- https://www.delveinsight.com/report-store/oropharyngeal-cancer-market
Thyroid Cancer Market- https://www.delveinsight.com/report-store/thyroid-cancer-market
Paranasal Sinus Cancer Market- https://www.delveinsight.com/report-store/paranasal-sinus-cancer-market
Castration-resistant Prostate Cancer Market- https://www.delveinsight.com/report-store/castration-resistant-prostate-cancer-crpc-market
Opioid Withdrawal Syndrome Market- https://www.delveinsight.com/report-store/opioid-withdrawal-syndrome-market
Complicated Urinary Tract Infections Market- https://www.delveinsight.com/report-store/complicated-urinary-tract-infections-market
Cervical Dystonia Market- https://www.delveinsight.com/report-store/cervical-dystonia-market
Schizophrenia Market- https://www.delveinsight.com/report-store/schizophrenia-market-insight
Focal Segmental Glomerulosclerosis Market- https://www.delveinsight.com/report-store/focal-segmental-glomerulosclerosis-fsgs-market
Obstructive Sleep Apnea Market- https://www.delveinsight.com/report-store/obstructive-sleep-apnea-osa-market
Severe Hypertriglyceridemia Market- https://www.delveinsight.com/report-store/severe-hypertriglyceridemia-shtg-market
Short Bowel Syndrome Market- https://www.delveinsight.com/report-store/short-bowel-syndrome-market
Complement 3 Glomerulopathy Market- https://www.delveinsight.com/report-store/complement-3-glomerulopathy-c3g-market
Aplastic Anemia Market- https://www.delveinsight.com/report-store/aplastic-anemia-market
Nephrotic Syndrome Market- https://www.delveinsight.com/report-store/nephrotic-syndrome-market
Pulmonary Arterial Hypertension Market- https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-market
Hemophilia A Market- https://www.delveinsight.com/report-store/hemophilia-a2030-market
Complicated Urinary Tract Infections Market- https://www.delveinsight.com/report-store/complicated-urinary-tract-infections-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:- https://www.delveinsight.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Adrenoleukodystrophy Pipeline 2024 | Bluebird bio, Applied Genetic Technologies Corporation, Poxel, Minoryx Therapeutics, Orpheris, MedDay Pharmaceuticals, Viking Therapeutics, and others. here

News-ID: 3543734 • Views:

More Releases from DelveInsight Business Research LLP

Hidradenitis Suppurativa Drugs Market Size 2034 | Inflarx, Novartis Pharmaceuticals, Incyte Corporation, UCB Biopharma, Janssen Pharmaceuticals, Novartis Pharmaceuticals, Amgen, Chemocentryx, Priovant Therapeutics, Pfizer, Anaptysbio, Abbvie, Acelyrin, Ac
Hidradenitis Suppurativa Drugs Market Size 2034 | Inflarx, Novartis Pharmaceutic …
DelveInsight's "Hidradenitis Suppurativa Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of Hidradenitis Suppurativa, historical and forecasted epidemiology as well as the Hidradenitis Suppurativa market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan. Key Takeaways from the Hidradenitis Suppurativa Market • Currently only HUMIRA is approved for the treatment of moderate to severe hidradenitis suppurativa with mode stefficacy
Glaucoma Drugs Market Size 2032 | Allergan, Sun Pharma Advanced Research Company Limited, Santen Pharmaceutical Co., Ltd., D.Western Therapeutics Institute (DWTI), Kowa Ltd., Alcon, Senju Pharmaceuticals and Otsuka Pharmaceuticals Co. Ltd., TearClear, Per
Glaucoma Drugs Market Size 2032 | Allergan, Sun Pharma Advanced Research Company …
DelveInsight's "Glaucoma Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Glaucoma, historical and forecasted epidemiology and the Glaucoma market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. Key Takeaways from the Glaucoma Market • According to DelveInsight's analysis, the total diagnosed prevalent cases of Glaucoma in 7MM were found to be 7,045,443 in 2022 and are
Retinitis Pigmentosa Drugs Market Size 2032 | Johnson & Johnson Innovative Medicine, MeiraGTx, Beacon Therapeutics, Nanoscope Therapeutics, Gensight Biologics, 4D Molecular Therapeutics, Coave Therapeutics, Ocugen, Bionic Sight, jCyte, Endogena Therapeuti
Retinitis Pigmentosa Drugs Market Size 2032 | Johnson & Johnson Innovative Medic …
DelveInsight's "Retinitis Pigmentosa Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of historical and forecasted epidemiology as well as the Retinitis Pigmentosa market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan. Key Takeaways from the Retinitis Pigmentosa Market Report • July 2024:- Janssen Pharmaceuticals- The purpose of the study is to assess the safety and tolerability of bilateral subretinal
Peanut Allergy Drugs Market Size 2032 | Parexel, Regeneron Pharmaceuticals, Sanofi, Aimmune Therapeutics Inc., AnaptysBio Inc., DBV Technologies, Aravax Pty Ltd, Astellas Pharma, Vedanta Biosciences Inc., Novartis Pharmaceuticals, Genentech Inc., and othe
Peanut Allergy Drugs Market Size 2032 | Parexel, Regeneron Pharmaceuticals, Sano …
DelveInsight's "Peanut Allergy Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Peanut Allergy, historical and forecasted epidemiology as well as the Peanut Allergy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Key Takeaways from the Peanut Allergy Market Report • The increased number of peanut allergy cases, along with the emerging treatment, is likely to contribute directly to the

All 5 Releases


More Releases for Adrenoleukodystrophy

Adrenoleukodystrophy (ADL) – Competitive Landscape, Epidemiology Forecast, and …
Adrenoleukodystrophy (ADL) is defined as a X-linked disorder which is more prominent in males. This disorder affects the adrenal glands. In this disease the fatty covering over the neurons and spinal cord starts deteriorating, thus reducing nerve’s ability to transfer the information. The damage to adrenal glands leads to reduction in the level of adrenocortical hormones. Download the sample report at: https://www.pharmaproff.com/request-sample/1156 This reduced level in turn causes weakness, weight loss,
In-Depth Forecast & Analysis on Adrenoleukodystrophy Market for 2017-2025
Adrenoleukodystrophy is also known as Adrenomyeloneuropathy or Schilder-Addison Complex, it is a hereditary condition that damages the myelin sheath (membrane surrounding nerve cells in your brain) and disrupts the breakdown process of long-chain fatty acids (VLCFA). Adrenoleukodystrophy is passed down from parents to their children in a form of X-linked genetic trait. The genetic trait causes deposition of very-long chain fatty acids in the body tissues due to impaired beta
Adrenoleukodystrophy Market to Witness Exponential Growth by 2025
Adrenoleukodystrophy is also known as Adrenomyeloneuropathy or Schilder-Addison Complex, it is a hereditary condition that damages the myelin sheath (membrane surrounding nerve cells in your brain) and disrupts the breakdown process of long-chain fatty acids (VLCFA). Adrenoleukodystrophy is passed down from parents to their children in a form of X-linked genetic trait. The genetic trait causes deposition of very-long chain fatty acids in the body tissues due to impaired beta
Global Adrenoleukodystrophy Drugs Market Size, Share, Outlook and Forecast Repor …
A fresh report has been added to the wide database of Market Research Hub (MRH). The research study is titled “Global Adrenoleukodystrophy Drugs Market Size, Share, Outlook and Forecast Report by 2018-2025”which encloses important data about the production, consumption, revenue and market share, merged with information related to the market scope and product overview. The report anticipates that the sector for pharmaceutical industry would rise at a positive CAGR during
Key Factors Contributing Towards Growth of the Adrenoleukodystrophy Market Durin …
Adrenoleukodystrophy is also known as Adrenomyeloneuropathy or Schilder-Addison Complex, it is a hereditary condition that damages the myelin sheath (membrane surrounding nerve cells in your brain) and disrupts the breakdown process of long-chain fatty acids (VLCFA). Adrenoleukodystrophy is passed down from parents to their children in a form of X-linked genetic trait. The genetic trait causes deposition of very-long chain fatty acids in the body tissues due to impaired beta
Innovations to Play a Vital Role in Adrenoleukodystrophy Market Growth
Adrenoleukodystrophy is also known as Adrenomyeloneuropathy or Schilder-Addison Complex, it is a hereditary condition that damages the myelin sheath (membrane surrounding nerve cells in your brain) and disrupts the breakdown process of long-chain fatty acids (VLCFA). Adrenoleukodystrophy is passed down from parents to their children in a form of X-linked genetic trait. The genetic trait causes deposition of very-long chain fatty acids in the body tissues due to impaired beta